Clinical Trial Update: Study of KN026 in Combination With Docetaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update of KN026 in combination with docetaxel as neoadjuvant therapy for HER2-positive breast cancer (status unknown).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• KN026

Snippet

Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Conditions: Breast Cancer | Phase 2 | Status: UNKNOWN